Skip to content
value.today
Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc.

INO
$144 Mmarket cap on Oct 30, 2026-7.5% since Jan 2024
Compare
World rank
#17,417
Revenue
$0 M
For year ending December-2025
Net income
$-85 M
-121357.1% margin
SEC filing
Employees
317
As on 2021
value.today research

Inovio Pharmaceuticals, Inc. in brief

Inovio Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Plymouth Meeting, Pennsylvania, USA. It was founded in 1979. Its market value was $144 M on 30 October 2026, which makes it the 17,417th largest listed company in the world and the 3,323rd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $85 M. It employs about 317 people and Jacqueline Elizabeth Shea is its chief executive. Its largest business segments by sales in 2025 were Reportable Segments (100%). Its shares trade under the symbol INO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Inovio Pharmaceuticals, Inc. timeline

5 events, 1983–2018
  1. 1983
  2. 🏁
    · approximate
    Founded
  3. 1999
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2005
  6. ✎
    Renamed Inovio Biomedical Corp
    Formerly Genetronics Biomedical Ltd.
  7. 2010
  8. ✎
    Renamed Inovio Pharmaceuticals, Inc.
    Formerly Inovio Biomedical Corp.
  9. 2018
  10. •
    Legal Entity Identifier issued
    LEI 529900B9W875XDZXTM97 registered.

Events of Inovio Pharmaceuticals, Inc. from Wikidata, SEC EDGAR and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$409 M$818 M$1.2 B$1.6 B2020202120222023202420252026

World rank over time

▼ down 4,007 places since 2020
2020-01-01: #13445#13,44520202021-01-01: #6373#6,37320212022-01-07: #9582#9,58220222022-12-25: #14195#14,19520222023-07-30: #19972#19,97220232024-01-05: #19187#19,18720242026-03-08: #9741#9,74120262026-08-01: #17027#17,02720262026-10-14: #16588#16,58820262026-10-30: #17452#17,4522026

Rank in USA: #2,841 (Jan 2020) · #1,851 (Jan 2021) · #2,570 (Jan 2022) · #2,911 (Dec 2022) · #3,919 (Jul 2023) · #3,414 (Jan 2024) · #1,896 (Mar 2026) · #3,371 (Aug 2026) · #3,176 (Oct 2026) · #3,327 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
2060.4×
Price / book
6.0×
Free cash flow yield
-61.7%
Net margin
-121357.1%
Operating margin
-124028.6%
Return on equity
-352.5%
Liabilities / assets
67.6%
Net debt
$-24M
Revenue growth
-68.2%
R&D / revenue
77442.9%
Revenue per employee
$0 K
Profit per employee
$-268 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $30M, net income $-97M$30MFY18Fiscal year ending Dec 2019: revenue $4M, net income $-119M$4MFY19Fiscal year ending Dec 2020: revenue $7M, net income $-166M$7MFY20Fiscal year ending Dec 2021: revenue —, net income $-304M—FY21Fiscal year ending Dec 2022: revenue $10M, net income $-280M$10MFY22Fiscal year ending Dec 2023: revenue $1M, net income $-135M$1MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-107M$0MFY24Fiscal year ending Dec 2025: revenue $0M, net income $-85M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M-68.2%$-87M$-85M-121357.1%
Dec 2024$0M-73.5%$-112M$-107M-48750.0%
Dec 2023$1M-91.9%$-144M$-135M-16279.5%
Dec 2022$10M—$-268M$-280M-2727.3%
Dec 2021——$-301M$-304M—
Dec 2020$7M+80.3%$-124M$-166M-2245.7%
Dec 2019$4M-86.5%$-111M$-119M-2904.1%
Dec 2018$30M—$-94M$-97M-318.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-89M$0M$-89M$-1.81—
Dec 2024$-104M$0M$-105M$-3.95—
Dec 2023$-124M$0M$-125M$-6.09—
Dec 2022$-216M$1M$-217M$-14.07—
Dec 2021$-216M$1M$-217M$-17.45—
Dec 2020$-178M$2M$-180M$-1.07—
Dec 2019$-98M$1M$-99M$-1.21—
Dec 2018$-74M$2M$-76M$-1.05—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-19M—Dec ’24Three months to Mar 2025: revenue $0M, net income $-20M$0MMar ’25Three months to Jun 2025: revenue —, net income $-24M—Jun ’25Three months to Sep 2025: revenue —, net income $-46M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $4M—Dec ’25Three months to Mar 2026: revenue —, net income $-20M—Mar ’26Three months to Jun 2026: revenue —, net income $-6M—Jun ’26Three months to Sep 2026: revenue $0M, net income $-49M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M, net income $-49M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Inovio Pharmaceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-87 M
Net income
$-85 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$74 M
Total liabilities
$50 M
Total equity
$24 M

As of December-2025

Top 100 institutional investors in Inovio Pharmaceuticals, Inc.#

As of Sep 30, 2026
111 institutions held 62.8 M shares (about 33.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 28.0%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Inovio Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1FMR LLC16,818,985+8,364,188 (+98.93%)8.98%$21 MNov 10, 2026
2Janus Henderson Group Ltd.10,434,210—5.57%$13 MNov 16, 2026
3Ra Capital Management, L.P.7,220,384New3.85%$9 MNov 16, 2026
4Vanguard Capital Management LLC4,599,357+948,795 (+25.99%)2.46%$6 MNov 13, 2026
5Citadel Advisors LLC3,126,541+2,884,766 (+1193.16%)1.67%$4 MNov 16, 2026
6Two Sigma Investments, LP2,539,360+1,299,582 (+104.82%)1.36%$3 MNov 16, 2026
7D. E. Shaw & Co., Inc.2,468,480+1,116,824 (+82.63%)1.32%$3 MNov 16, 2026
8Marshall Wace, LLP2,279,039New1.22%$3 MNov 13, 2026
9Renaissance Technologies LLC1,513,187+1,151,848 (+318.77%)0.81%$2 MNov 12, 2026
10ADAR1 Capital Management, LLC1,444,165-699,745 (-32.64%)0.77%$2 MNov 16, 2026
11Eversept Partners, LP1,381,201+345,841 (+33.40%)0.74%$2 MNov 16, 2026
12Geode Capital Management, LLC1,000,027+197,276 (+24.57%)0.53%$1 MNov 6, 2026
13Quadrature Capital Ltd875,116+616,188 (+237.98%)0.47%$1 MNov 13, 2026
14BlackRock, Inc.763,813-15,244 (-1.96%)0.41%$1 MNov 13, 2026
15Jane Street Group, LLC732,944+608,419 (+488.59%)0.39%$1 MNov 12, 2026
16Vanguard Fiduciary Trust Co622,858+142,089 (+29.55%)0.33%$1 MNov 13, 2026
17Jacobs Levy Equity Management, Inc559,137New0.30%$1 MNov 16, 2026
18HRT Financial LP491,484+351,052 (+249.98%)0.26%$1 MNov 13, 2026
19UBS Group AG383,008+120,688 (+46.01%)0.20%$0 MNov 10, 2026
20State Street Corp354,210+17,600 (+5.23%)0.19%$0 MNov 12, 2026
21Jpmorgan Chase & Co344,964+344,918 (+749821.74%)0.18%$0 MNov 12, 2026
22XTX Topco Ltd329,286+223,453 (+211.14%)0.18%$0 MNov 16, 2026
23Bank Of America Corp /de/297,355New0.16%$0 MNov 16, 2026
24Northern Trust Corp235,260+60,866 (+34.90%)0.13%$0 MNov 16, 2026
25Gsa Capital Partners LLP151,767-113,244 (-42.73%)0.08%$0 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Inovio Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Seven Fleet Capital Management LP137,100New0.07%$0 MNov 16, 2026
27DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main133,6480 (0.00%)0.07%$0 MNov 16, 2026
28GMT Capital Corp126,1190 (0.00%)0.07%$0 MNov 16, 2026
29Green Alpha Advisors, LLC114,857+46,802 (+68.77%)0.06%$0 MOct 8, 2026
30Goldman Sachs Group Inc111,323+17,603 (+18.78%)0.06%$0 MNov 16, 2026
31Morgan Stanley106,112+55,856 (+111.14%)0.06%$0 MNov 13, 2026
32Millennium Management LLC97,963-698,144 (-87.69%)0.05%$0 MNov 16, 2026
33LexAurum Advisors, LLC97,100New0.05%$0 MOct 19, 2026
34Invesco Ltd.94,431+14,093 (+17.54%)0.05%$0 MNov 12, 2026
35Graham Capital Management, L.P.93,305New0.05%$0 MNov 16, 2026
36Virtu Financial LLC93,083New0.05%$0 MNov 17, 2026
37Greenwich Wealth Management LLC88,598+56,599 (+176.88%)0.05%$0 MNov 12, 2026
38Prime Capital Investment Advisors, LLC70,636+53,510 (+312.45%)0.04%$0 MOct 20, 2026
39Raymond James Financial Inc41,412-874 (-2.07%)0.02%$0 MNov 12, 2026
40Vestmark Advisory Solutions, Inc.38,761New0.02%$0 MNov 16, 2026
41Elevation Point Wealth Partners, LLC38,761New0.02%$0 MNov 5, 2026
42Hudson Bay Capital Management LP35,390New0.02%$0 MNov 13, 2026
43Vanguard Global Advisers, LLC30,2350 (0.00%)0.02%$0 MNov 13, 2026
44Susquehanna International Group, LLP27,502New0.01%$0 MNov 16, 2026
45Zacks Investment Management26,082-353 (-1.34%)0.01%$0 MNov 16, 2026
46HighTower Advisors, LLC26,076+13,346 (+104.84%)0.01%$0 MNov 10, 2026
47Engineers Gate Manager LP23,357-10,334 (-30.67%)0.01%$0 MNov 16, 2026
48LPL Financial LLC23,227+6,113 (+35.72%)0.01%$0 MNov 6, 2026
49StoneX Group Inc.17,134+2,882 (+20.22%)0.01%$0 MNov 3, 2026
50Qube Research & Technologies Ltd13,244New0.01%$0 MNov 13, 2026
51Wells Fargo & Company/mn12,981+9,721 (+298.19%)0.01%$0 MNov 16, 2026
52BNP Paribas Financial Markets12,814+12,462 (+3540.34%)0.01%$0 MNov 12, 2026
53Mayflower Financial Advisors, LLC12,5590 (0.00%)0.01%$0 MNov 10, 2026
54Point72 Asset Management, L.P.11,868New0.01%$0 MNov 16, 2026
55SBI Securities Co., Ltd.11,328+4,514 (+66.25%)0.01%$0 MOct 22, 2026
56Signature Estate & Investment Advisors LLC11,0280 (0.00%)0.01%$0 MOct 13, 2026
57Stephens Inc /ar/10,500-5,000 (-32.26%)0.01%$0 MNov 12, 2026
58Royal Bank Of Canada8,231+3,979 (+93.58%)0.00%$0 MNov 16, 2026
59Covestor Ltd5,1200 (0.00%)0.00%$0 MOct 30, 2026
60Simplex Trading, LLC3,609New0.00%$0 MNov 4, 2026
61Barclays PLC2,826-661 (-18.96%)0.00%$0 MNov 6, 2026
62Rockefeller Capital Management L.P.2,1030 (0.00%)0.00%$0 MNov 13, 2026
63Citigroup Inc1,502New0.00%$0 MNov 4, 2026
64Activest Wealth Management1,5000 (0.00%)0.00%$0 MOct 15, 2026
65Steward Partners Investment Advisory, LLC1,281-100 (-7.24%)0.00%$0 MNov 13, 2026
66BFC Planning, Inc.963+12 (+1.26%)0.00%$0 MNov 13, 2026
67Osaic Holdings, Inc.830-103 (-11.04%)0.00%$0 MNov 12, 2026
68Federation des caisses Desjardins du Quebec6410 (0.00%)0.00%$0 MNov 16, 2026
69Toronto Dominion Bank606New0.00%$0 MNov 16, 2026
70NFSG Corp3590 (0.00%)0.00%$0 MOct 15, 2026
71Jones Financial Companies Lllp316+76 (+31.67%)0.00%$0 MNov 13, 2026
72PNC Financial Services Group, Inc.3000 (0.00%)0.00%$0 MNov 6, 2026
73Pioneer Family Office, LLC2910 (0.00%)0.00%$0 MOct 30, 2026
74Harbour Investments, Inc.241+4 (+1.69%)0.00%$0 MNov 9, 2026
75Root Financial Partners, LLC210New0.00%$0 MOct 21, 2026
76Bolton Securities Corporation2080 (0.00%)0.00%$0 MNov 12, 2026
77Arax Advisory Partners203+100 (+97.09%)0.00%$0 MNov 12, 2026
78Decker Retirement Planning Inc.1680 (0.00%)0.00%$0 MOct 19, 2026
79Robinhood Markets, Inc.120—0.00%$0 MNov 18, 2026
80Farther Finance Advisors, LLC1110 (0.00%)0.00%$0 MOct 8, 2026
81Tower Research Capital LLC (TRC)104-13,197 (-99.22%)0.00%$0 MNov 16, 2026
82Northwestern Mutual Wealth Management Co83+75 (+937.50%)0.00%$0 MNov 13, 2026
83Blume Capital Management, Inc.830 (0.00%)0.00%$0 MOct 26, 2026
84Smartleaf Asset Management LLC830 (0.00%)0.00%$0 MNov 10, 2026
85Rydar Equities, Inc.83New0.00%$0 MOct 13, 2026
86Pittenger & Anderson Inc770 (0.00%)0.00%$0 MNov 2, 2026
87National Bank Of Canada /fi/580 (0.00%)0.00%$0 MNov 16, 2026
88Mcdonald Partners LLC580 (0.00%)0.00%$0 MNov 3, 2026
89Allworth Financial LP470 (0.00%)0.00%$0 MNov 17, 2026
90Pinnacle Wealth Planning Services, Inc.410 (0.00%)0.00%$0 MOct 27, 2026
91TD Waterhouse Canada Inc.41-2,342 (-98.28%)0.00%$0 MOct 16, 2026
92Nova Financial LLC410 (0.00%)0.00%$0 MNov 4, 2026
93Pinnacle Financial Group, Inc.39—0.00%$0 MNov 16, 2026
94Valley National Advisers Inc240 (0.00%)0.00%$0 MOct 23, 2026
95Atwood & Palmer Inc180 (0.00%)0.00%$0 MOct 8, 2026
96CoreCap Advisors, LLC160 (0.00%)0.00%$0 MOct 8, 2026
97Key Financial Inc140 (0.00%)0.00%$0 MNov 2, 2026
98Thompson Investment Management, Inc.130 (0.00%)0.00%$0 MOct 14, 2026
99Golden State Wealth Management, LLC100 (0.00%)0.00%$0 MNov 2, 2026
100Strategic Financial Concepts, LLC10New0.00%$0 MNov 16, 2026

All 111 institutional investors, with who bought and sold →

Mutual funds holding Inovio Pharmaceuticals, Inc.#

17 funds hold shares worth $14 M (about 9.7% of the company). Since their previous reports 15 added shares and 3 sold, buying $4 M net.
Mutual funds holding Inovio Pharmaceuticals, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC6.99 M$5 M3.7%0.05%+24%Jul 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.60 M$3 M1.4%<0.01%+25%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC3.54 M$2 M1.9%0.05%+25%Jul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.963,325$1 M0.51%<0.01%+30%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC1.92 M$1 M1.0%0.01%newJul 31, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC1.00 M$0 M0.54%0.01%newJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC348,001$0 M0.19%<0.01%+1.6%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors280,138$0 M0.15%0.02%+64%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC104,005$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC96,119$0 M0.05%<0.01%+9.7%May 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.67,976$0 M0.04%<0.01%+150%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC45,041$0 M0.02%<0.01%−19%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.45,128$0 M0.02%<0.01%+16%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.42,017$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC21,590$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC18,882$0 M0.01%<0.01%+60%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC5,208$0 M<0.01%<0.01%+417%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,613$0 M<0.01%<0.01%+28%Jun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC464$0 M<0.01%<0.01%+29%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 19 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Inovio Pharmaceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
21
since
Inovio Pharmaceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jacqueline Elizabeth SheaChief Executive Officer, DirectorOption exercise+28,296——123,327Form 4
filed Laurent HumeauChief Scientific OfficerOption exercise+6,027——48,986Form 4
filed Peter KiesCFOOption exercise+8,700——47,542Form 4
filed Michael John SumnerChief Medical OfficerOption exercise+9,450——44,731Form 4
filed Michael John SumnerChief Medical OfficerShares withheld for tax-2,693$1.230$3 K42,038Form 4
filed Jacqueline Elizabeth SheaChief Executive Officer, DirectorShares withheld for tax-12,306$1.230$15 K111,021Form 4
filed Peter KiesCFOShares withheld for tax-4,688$1.230$6 K42,854Form 4
filed Laurent HumeauChief Scientific OfficerShares withheld for tax-2,163$1.230$3 K46,823Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Inovio Pharmaceuticals, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
22.1 M
32.0% of shares · 1.82 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-12 reverse split ; 1-for-4 reverse split

Fails to deliver

  • : 10,000 shares at $0.77
  • : 1,486 shares at $0.93
  • : 1,502 shares at $0.89
  • : 450 shares at $0.90
  • : 93 shares at $0.84

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Inovio Pharmaceuticals, Inc. scorecard#

Passes 2 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median6.0×Price to book 6.0× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-61.6%Free cash flow is -61.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.81 vs -3.95Diluted EPS -1.81 in fiscal 2025 against -3.95 the year before (report's currency).
    • ✓Net income higher than five years earlier-$85 M-$85 M in fiscal 2025 against -$166 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$85 MNet income -$85 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-183.5%-183.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.4×Current ratio 1.40 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-36.05Z-score -36.05 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year72.6%Diluted shares up 72.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Inovio Pharmaceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Inovio Pharmaceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.10.20.8101.87.44.1304235
Research and development5476871882499488959989
General and administrative33374890543727292824
Operating expenses87113145278303131115125126112
Operating income−87−112−144−268−301−124−111−94−84−76
Interest and finance income2.44.88.1———————
Interest expense and finance costs00.21.21.31.98.77.900.0—
Share of profit of associates——0−2.2−0.4−4.600——
Other non-operating income (expense)−2.6−3.2−4.7−3.90.3−0.70.5−1.3−0.2—
Income before tax−85−107−135−278−303−163−121−95−88−74
Income tax000000−0.32.200
Net income including minority interests———−280−304−167−121−97−88−74
Minority interests' share of net income———00−1.1−1.2000
Net income attributable to shareholders−85−107−135−280−304−166−119−97−88−74
Earnings per share, basic-1.81-3.95-6.09-14.07r-17.45r-1.07-1.21-1.05-1.08-1.01
Earnings per share, diluted-1.81-3.95-6.09-14.07r-17.45r-1.07-1.21-1.05-1.09-1.01
Shares, weighted average (basic)47272220r17r15599938273
Shares, weighted average (diluted)47272220r17r15599938273
Balance sheet
Cash and cash equivalents446614467125122242419
Short-term investments1428131207330161675810486
Receivables0.01.22.41.75.5190.73.36.016
Other current assets2.63.7r5.4r5039401.61.42.61.7
Current assets61981533154484719488138125
Property, plant and equipment2.53.75.07.717111316189.0
Right-of-use (leased) assets6.58.19.510121314———
Goodwill——011111111111111
Other intangible assets——02.12.63.13.74.86.07.6
Investments in associates————00.40———
Long-term investments———————9.4——
Total assets74113171349496540144131187174
Accounts payable———80482118232320
Current liabilities44354397664232353544
Lease liabilities (non-current)6.59.41113151820———
Total liabilities5045541269679139444550
Retained earnings−1,815−1,730−1,623−1,488−1,210−906−740−620−523−435
Shareholders' equity24691172224004613.487142123
Minority interests—————02.00.10.10.1
Total equity———2224004615.487142123
Total liabilities and equity74113171349496540144131187174
Shares outstanding69362321r217187101979074
Cash-flow statement
Share-based compensation3.86.61123261611111310
Cash from operating activities−89−104−124−216−216−178−98−74−63−63
Capital expenditure−0.3−0.5−0.3−1.0−1.2−1.5−1.0−2.1−10−2.7
Intangible assets bought———————00−1.2
Cash from investing activities1410487110−175−59−9.042−2816
Debt issued————009700—
Shares issued35365.5832094549.129946.3
Cash from financing activities53515.08221146510531967.8
Exchange-rate effect on cash00.0−0.0−0.0−0.00.00r000
Change in cash−2252−32−25−180229−1.5−0.14.7−38
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Inovio Pharmaceuticals, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Reportable Segments$0 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Inovio Pharmaceuticals, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.6 M
Dr. Shea
Other top executives, average
$872 K
the CEO earned 1.8× this
$100 invested is now
$9
Inovio Pharmaceuticals, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Shea$1.6 M$1.5 M$872 K$9
2024Dr. Shea$2.1 M$904 K$989 K$10
2023Dr. Shea$2.4 M$1.1 M$1.2 M$33

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Inovio Pharmaceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 1 · Material agreement 8 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 13

Inovio Pharmaceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Material agreementShareholder rights changed8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Lobbying by Inovio Pharmaceuticals, Inc.#

$30 K spent on lobbying the US Congress and federal agencies in 2024.

Lobbying, 2024
$30 K
#1,301 among companies on value.today
Own lobbyists
Yes
files its own reports
Firms hired
0
in 2024
2026 so far
$60 K
Inovio Pharmaceuticals, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$60 K—1
2024$30 K$30 K2
2023$170 K$170 K4
2022$560 K$560 K10
2021$360 K—8
2020$90 K—3
2019$100 K—4
2018$120 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Inovio Pharmaceuticals”, “INOVIO PHARMACEUTICALS, INC.” and “Inovio Pharmaceuticals, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Layoffs at Inovio Pharmaceuticals, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
137
2019–2023
Latest
58 people
2023-07-31
Inovio Pharmaceuticals, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
202324·····58·····82
2022······55·····55
2019············—
Inovio Pharmaceuticals, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
58 people (30% of workforce)Restructuring planSEC 8-K“(the “ Company ”) committed to and communicated a corporate reorganization plan, including a reduction in force of 58 employees (the “ Reduction ”), representing approximately 30% …”Filing
24 people (11% of workforce)Restructuring planSEC 8-K“As part of the Reduction, the Company has reduced its overall headcount by approximately 24 employees, which represents 11% of its full-time employees.”Filing
55 people (18% of workforce)Restructuring planSEC 8-K“As part of the Reduction, the Company has reduced its overall headcount by approximately 55 employees, which represents 18% of its full-time employees.”Filing
28% of workforceRestructuring planSEC 8-K“In order to reduce operating expenses and conserve cash resources, the Company also announced a reduction of approximately 28% of its workforce and the discontinuation of its immun…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Inovio Pharmaceuticals, Inc. compares in Biotechnology

  • Market cap$144 M · higher than 41% of 726
  • Revenue$0 M · higher than 15% of 647
  • Revenue growth-68.2% · higher than 11% of 438
  • Price / book6.0× · lower than 26% of 534
  • FCF yield-61.6% · higher than 20% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Inovio Pharmaceuticals, Inc.🇺🇸$144 M——-68.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Inovio Pharmaceuticals, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Inovio Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Inovio Pharmaceuticals, Inc.? Suggest a correction